In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

This was the stock's second consecutive day of losses.

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The stock's fall snapped a four-day winning streak.

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Property News: The ATO's new move to claw back more than $1b from dodgy landlords. © 2025 Nine Entertainment Co.